ViiV Healthcare Reveals Positive Results from Phase I Trial for a Potential Longer-Acting HIV Treatment

Novel formulation of cabotegravir (CAB-ULA) allows for dosing intervals of at least four months.

Source link
#ViiV #Healthcare #Reveals #Positive #Results #Phase #Trial #Potential #LongerActing #HIV #Treatment